Table III.

Association of baseline plasma CRP levels and subsequent risk of colorectal cancer: SMHS (2002–06)

CRP (μg/ml)	Cases	Controls	RR (95% CI)a	RR (95% CI)b	RR (95% CI)c
Colorectal cancer
<0.45	60	192	1.0	1.0	1.0
0.45–1.19	94	191	1.63 (1.11–2.40)	1.51 (1.00–2.28)	1.61 (1.04–2.49)
>1.19	134	193	2.32 (1.59–3.38)	1.88 (1.24–2.86)	1.97 (1.26–3.08)
P for trend			<0.001	0.003	0.004
Colon cancer
<0.45	36	117	1.0	1.0	1.0
0.45–1.19	48	110	1.43 (0.86–2.36)	1.44 (0.83–2.49)	1.62 (0.90–2.93)
>1.19	88	117	2.45 (1.53–3.91)	2.05 (1.20–3.50)	2.23 (1.25–3.99)
P for trend			<0.001	0.008	0.007
Rectal cancer
<0.45	24	75	1.0	1.0	1.0
0.45–1.19	46	81	1.91 (1.04–3.50)	1.57 (0.82–3.01)	1.57 (0.80–3.08)
>1.19	46	76	2.08 (1.11–3.91)	1.61 (0.81–3.21)	1.58 (0.76–3.30)
P for trend			0.031	0.213	0.256

^aConditional logistic regression.

^bStratified by matched sets and adjusted for smoking status, regular exercise, BMI, WHR, family history of cancer, number of selected diseases reported at baseline, use of antibiotics in the 7 days before blood collection, use of antihypertension medication and ever use of non-steroidal anti-inflammatory drugs.

^cExcluding men who had used antibiotics in the 7 days before blood collection.